It is made available under a CC-BY-NC-ND 4.0 International license .

1 Coronavirus and Post-COVID-19 Syndrome: A Systematic Review

- 2 Sarvinoz Albalushi^{*1}, Azmaeen Zarif^{*,†,2,3}, Suheyla Karaduman⁴, Alesia Talpeka^{5,6}, Khoa Tran⁷
- 3
- ⁴ ¹University of Debrecan, Debrecen, Egyetem tér 1, 4032 Hungary
- 5 ² University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge,
- 6 Cambridgeshire, CB2 0SP, United Kingdom
- 7 ³ Gonville & Caius College, University of Cambridge, Trinity Street, Cambridge, Cambridgeshire, CB2 1TA,
- 8 United Kingdom
- 9 ⁴ Uludag University Medical School, Özlüce, Uludağ Ünv., 16285 Nilüfer/Bursa, Türkiye
- ⁵ Belarusian State Medical University, Prospekt Dzerzhinskogo 83, Minsk 220116, Belarus
- ⁶ Minsk City Clinical Oncology Center, 1st City Clinical Hospital, Nezavisimosti Svenue, 64, Minsk 220040
- ⁷ Pham Ngoc Thach University of Medicine, 2 Đ. Dương Quang Trung, Phường 12, Quận 10, Thành phố Hồ
 Chí Minh, Vietnam
- 13 Chí Minh, Vietnam
- 14
- 15 [†] Corresponding author:
- 16 Azmaeen Zarif
- 17 Gonville & Caius College
- 18 University of Cambridge
- 19 Trinity Street
- 20 Cambridge
- 21 Cambridgeshire
- 22 CB2 1TA
- 23 United Kingdom
- Email: az397@cam.ac.uk
- 25

It is made available under a CC-BY-NC-ND 4.0 International license .

26 Abstract

27

28 Coronavirus infectious Disease 2019 (COVID-19) was first reported in Wuhan, China, and with its 29 rapidly mutating variants, it soon became a global concern. In response to the pandemic, intensive 30 research and development efforts led to the development of six vaccines approved by the World Health 31 Organization (WHO). Coronavirus is divided into four genera: alpha, beta, gamma and delta. Its unstable 32 ssRNA resulted in multiple strains in a short period, which acted as a selection pressure for 33 transmissibility. Sequelae of COVID-19 infection include multiple syndromes which have been reported 34 at high incidence globally. Using the Cochrane guidelines and the Preferred Reporting Items for 35 Systematic Reviews and Meta-Analyses (PRISMA), we present a systematic review of the most common 36 syndromes reported. A total of 12 eligible studies were included in this review. Syndromes reported in the 37 literature include immune thrombocytopenic purpura (ITP), viral encephalomyelitis, hemophagocytic 38 lymphohistiocytosis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barrè syndrome (GBS) and 39 postural orthostatic tachycardia syndrome (POTS). We cover the hypothesized pathophysiology, 40 presenting symptoms and treatment for each respective syndrome. We aim to discuss coronavirus and its 41 variants to provide a foundation on which to examine the syndromes manifested after COVID-19 42 infection (post-COVID-19 syndrome).

43

44 Keywords: COVID-19, Guillain-Barrè Syndrome, Hemophagocytic Lymphohistiocytosis, Immune

45 Thrombocytopenic Purpura, Postural Orthostatic Tachycardia Syndrome, single stranded ribonucleic acid,

- 46 Thrombotic Thrombocytopenic Purpura
- 47
- 48
- 49
- 50
- 51

It is made available under a CC-BY-NC-ND 4.0 International license .

52 Introduction

53

54 Background

55 The first cases of Coronavirus infectious Disease 2019 (COVID-19), an infectious disease caused by the 56 SARS-CoV-2 virus, were reported in Wuhan, China in late December 2019 (Li et al., 2020; Roy, Roy & 57 Paul, 2020). The first four cases were reported as respiratory illnesses and initially referred to as 58 'pneumonia of unknown etiology', which later emerged as the global COVID-19 pandemic (Tan et al., 59 2020). Since its emergence, several variants have emerged. Despite strict preventive measures (sanitizing 60 probable fomites, wearing face masks, regular hand washing, promoting personal hygiene, and using 61 alcohol-based hand sanitizers) recommended by the Centers for Disease Prevention and Cure (CDC) and 62 World Health Organisation (WHO), the number of affected individuals till date has reached 695 million 63 where 6.9 million individuals died and 667 million recovered (Worldometer. (n.d.)).

64

65 In response to the pandemic, groundbreaking efforts were made by scientists in collaboration with 66 pharmaceutical companies to develop six COVID-19 vaccines approved by the WHO's Strategic 67 Advisory Group of Experts on Immunization (SAGE). These vaccines included BNT162b2 mRNA 68 (Pfizer), mRNA-1273 (Moderna), and Janssen Ad26.CoV2.S (Johnson & Johnson), AZD1222 69 (Oxford/AstraZeneca), CoronaVac (Sinovac Biotech), and BBIBP-CorV (Sinopharm). According to the 70 WHO, by March 2022, 90% of the global population had antibodies against COVID-19 disease either 71 through infection or through vaccination (WHO, 2022a). Alongside the development and mass 72 administration of vaccines, several mutants of SARS-CoV-2 have been identified across the globe, which 73 resulted in subsequent infection cycles and an exponential expansion in the geographical range of the 74 disease.

75

Coronaviruses are a group of single-stranded RNA (ssRNA) viruses that fall under the family
Coronaviridae, subfamily Coronavirinae, and order Nidovirales. These viruses transmit infection from

It is made available under a CC-BY-NC-ND 4.0 International license .

78 human to human and also infect birds (Yousefi & Eslami, 2022). These viruses were documented almost 79 50 years ago and over these five decades, different viruses from this family have been identified in 80 different areas of the globe. The viruses can be divided into four different genera: Alpha coronavirus (also 81 known as human coronaviruses, HCoVs), Beta coronavirus (this category includes Middle Eastern 82 Respiratory syndrome-related coronavirus, MERS-CoV, and the widely-known SARS-CoV), Gamma 83 coronavirus, and Delta coronavirus. The viruses from the last two genera mostly infect birds (Nakagawa, 84 Lokugamage, & Makino, 2016). Based on the similarity of a sequence of nucleic acid, the newly 85 identified Severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2) can be categorized as beta 86 coronavirus (Xiao et al., 2020).

87

88

89 Variants of Coronavirus

90 SARS-CoV-2 is an RNA virus with an unstable genome. This poses a constant threat of developing
91 mutant strains that may become dominant through natural selection, often with higher transmissibility
92 than previous strains.

93

94 Throughout the pandemic, several variants of SARS-CoV-2 have emerged. These mutations can be 95 caused by environmental mutagens such as metal ions and UV radiation, as well as endogenous 96 components of the virus (Sanjuán & Domingo-Calap, 2016). Typically, RNA viruses evolve gradually 97 over time (Morley & Turner, 2017). During the pandemic, the WHO collaborated with national and 98 international researchers to monitor the changes in the patterns of transmission of SARS-CoV-2, its 99 clinical presentation, severity, and impact on public health measures. The WHO established close 100 monitoring networks to identify potential Variants of Interest (VOIs) and Variants of Concern (VOCs) 101 and to assess their risk to public health (WHO, 2022b). To date, four VOCs have been identified: Alpha, 102 Beta, Gamma, and Delta.

It is made available under a CC-BY-NC-ND 4.0 International license .

The Beta variant (B.1.351) was first identified in South Africa in May 2020. This variant has been found to affect younger people more severely than previous strains. Since its initial detection, it has been identified in 80 countries and was thought to be the main cause of the third wave of the pandemic in South Africa. Of particular concern is the E484K mutation found in this variant, which allows it to evade the immune system more easily (CDC, 2020).

109

110 The U.K. was the first location where the Alpha variant (B.1.1.7) was identified., and it was the prime 111 cause of the third wave in the U.K. This strain is not only highly transmissible but it is extremely lethal. It 112 is 30-70% more transmissible and lethal than the original strain (Raheem et al., 2021). Note that these 113 strains do not result from a single mutation but rather are the result of, to date, 149 mutations that have 114 been identified in more than a hundred sequenced strains since the beginning of the pandemic till May 115 2020 (Awadasseid et al., 2021). These mutations usually change the spike proteins of the virus. These 116 spike proteins are used by the virus to enter the cells in humans using the angiotensin-converting enzyme 117 2 (ACE2) receptor (Casalino et al., 2020). The first notable strain of the novel coronavirus, which became 118 a predomination globally, was the D614G variant, also known as G614. This variant was the result of a 119 missense mutation (23403A>G) of the S1 subunit (spike protein component). This mutation changed the 120 original strain (D614) that was identified in Wuhan. It was originally spotted in Europe and, within a 121 month, dominated the globe. The G614 variant had higher transmissibility than the original Wuhan 122 variant or any other variant (Korber et al., 2020). In addition to having a higher transmissibility, it was 123 also found to enhance the risk of death among individuals (Challen et al., 2021; Davies et al., 2020).

124

The Gamma variant (P.1) was first identified in Brazil in November 2020. It is twice as transmissible as the previous strain and was the primary cause of the second deadly wave of the coronavirus. Studies have shown that existing vaccines provide only 54-79% protection against this variant (WHO, 2022c).

It is made available under a CC-BY-NC-ND 4.0 International license .

129 The Delta variant (B.1.617.2) was first reported by the WHO on June 21, 2021. It is highly contagious 130 and, to date, the fastest-spreading strain. This variant targets vulnerable populations, especially in areas 131 with low COVID-19 vaccination rates. It was first identified in India, where it was 60% more 132 transmissible than other strains and posed a higher risk of reinfection (Cherian et al., 2021). The Delta 133 variant drove the second deadly wave of Coronavirus in India in the summer of 2021, affecting vulnerable 134 individuals with pre-existing conditions (Mallapaty et al., 2021). It spread to 92 countries, accounting for 135 20% of new cases in the US and 60% of new infections in the UK (Mishra et al., 2021). A mutation in the 136 spike protein of the Delta virus has led to a new variant known as Delta plus, which has been found in 137 several countries, including Nepal, Portugal, the US, the UK, and Russia (Kupferschmidt & Wadman, 138 2021).

139

140 The Omicron variant (B.1.1.529) was first reported by WHO on November 24, 2021, and just two days 141 later it was declared a variant of concern due to its increased detection in the South African region and the 142 identification of several mutations in the spike protein, particularly in the immunogenic region (WHO, 143 2021). This variant has nearly 32 mutations in the spike protein and 10 mutations in the receptor-binding 144 domain. It was first identified in the U.S. and has since spread rapidly throughout the world. The 145 mutations in the spike protein have made it easier for the virus to infect human cells and evade the 146 immune response, making it more transmissible than previous strains. The most notable mutations are 147 N501Y, D614G, and E484K, which allow the virus to escape the protection offered by currently available 148 vaccines. These structural changes also distort the antibody binding sites, further compromising the 149 immune response to the infection (Kamble et al., 2022).

150

151 Composition and Genome Structure of Coronavirus

152 The family Coronaviridae encompasses the Coronavirus, which is further divided into two subfamilies:

153 Coronavirinae and Torovirinae. ssRNA and +ssRNA are about 26–32 kb in genome size. Coronaviruses

are typically classified into four genera based on their genomic structure and host range. The four genera

It is made available under a CC-BY-NC-ND 4.0 International license .

155 of Coronaviridae are Alpha, Beta, Gamma, and Delta Coronavirus. The Alpha and Beta genera primarily 156 infect mammals, while the Gamma and Delta genera primarily infect birds. Bats are the natural reservoir 157 of Coronaviruses, and they are mainly responsible for the spread of novel coronavirus (Li et al., 2019). 158 Coronavirus has at least 27 proteins including four structural proteins, 15 non-structural proteins, and 8 159 auxiliary proteins. Its envelope includes four spike-shaped proteins including envelope proteins (E), 160 glycoproteins (S), nucleocapsid (N), and membrane proteins (M). These proteins play a vital role in 161 binding to the host cell and facilitating entry of the virus. Sixteen non-structural proteins (nsp1-16) 162 constitute a viral transcriptase-replicase complex that is encoded by two polypeptides (pp1a and pp1ab). 163 These non-structural proteins are primarily involved in the formation of double-membraned vesicles that 164 are derived from the rough endoplasmic reticulum, which plays a crucial role in the replication and 165 transcription of the virus, serving as the primary site for these processes.

166

167 To reduce the number of mutations in the RNA genome, Coronavirus also encodes exoribonuclease 168 (EXoN) which is produced by the nsp14 protein. The spike protein is a key factor in the virus's ability to 169 enter host cells, with the receptor-binding domain (RBD) located in the S1 subunit responsible for 170 binding to the host cell receptor and the S2 subunit facilitating fusion of the viral and host cell membranes 171 (Chen, Liu & Guo, 2020).

172

Spike glycoprotein (S), a structural protein that is located on the outer envelope of the virus, attaches to the host-receptor angiotensin □ converting enzyme 2 (ACE2). The S protein of Coronavirus contains carboxyl (C)-terminal S2 subunit and amino (N)-terminal S1 subunit with a length ranging from 1104 to 1273 amino acids. The S1 subunit is the receptor-binding domain (RBD) which has an external subdomain and a core subdomain. These two subunits span around 200 residues. The core subdomain of RBD is primarily responsible for the formation of S trimer particles. The two exposed loops on the surface of the external subdomain are responsible for binding with ACE2.

It is made available under a CC-BY-NC-ND 4.0 International license .

181	Infection with	COVID-19 has	resulted in man	v different	nost-infective	syndromes	heing re	norted	termed
101	infection with	COVID-19 lias	s resulted in man	y unicient	post-intective s	synuromes	being re	poneu,	termeu

- 182 post-COVID syndrome. We attempted to systematically synthesize all the evidence available on sequelae
- 183 syndromes post-COVID-19 infection.
- 184

- 186 The guidelines of the Cochrane Handbook for a systematic review and the Preferred Reporting Items for
- 187 Systematic Reviews and Meta-Analyses (PRISMA) (Vrabel, 2015) statement were followed to structure
- 188 this systemic review (Higgins et al. 2019).
- 189
- 190 Search Strategy

191 A search strategy was established based on key terms for 'Syndrome' and 'COVID-19'. Moreover, MeSH

- terms were reviewed to add a term to the search strategy.
- 193
- 194 PubMed was searched using the search strategy given in Table 1 to ensure all the studies conducted were
- 195 captured. The search was limited to the last 4 years from 2019 (the emergence of COVID-19) to 2022.
- 196
- 197
- 198
- 199
- 200

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

205 **Table 1.** Search strategy for the review.

Step	Term	Search term
Step 1	Syndrome	'Syndromes' OR 'Symptom Cluster' OR 'Symptom Clusters'
Step 2	COVID-19	('COVID' OR 'COVID-19' OR 'nCoV' OR 'coronavirus' OR 'Middle East
		respiratory syndrome' OR 'MERS' OR 'Severe Acute Respiratory
		Syndrome' OR 'SARS')

206 207

208 S	creening	Process
-------	----------	---------

209 Searches were downloaded in the form of an Excel sheet. Duplicates were removed from the downloaded

210 searches. Titles and abstracts were screened based on inclusion and exclusion criteria (see below). Then,

211 full-length articles were screened using the same criteria. The PRISMA flowchart summarizes the

screening and selection process of the studies (see Supplementary Materials, Figure S1).

213

214 Determining the eligibility of the studies

Inclusion and exclusion criteria to determine the eligibility of screened studies for inclusion in the revieware detailed below.

- 218 Inclusion Criteria:
- All quantitative studies, case reports, and case series reports on any syndrome that occurred after
 COVID-19 infection
- Both males and females from any age group were included

It is made available under a CC-BY-NC-ND 4.0 International license .

222	Participants must have been diagnosed with COVID-19 infection
223	• Non-English studies were included if a full-text article was available in English
224	
225	Exclusion Criteria:
226	• Qualitative studies, literature reviews, editorials, and policy documents were excluded
227	• Studies conducted on patients with any other infection than COVID-19
228	• Studies not having the outcome of interest (i.e., post-COVID-19 infection syndrome)
229	• No full text of the study was available
230	
231	Inclusion and exclusion criteria based on intervention, comparator, population, and outcome of review
232	question are detailed in the Supplementary Materials (Table S1).
233	
234	Risk of Bias
235	The risk of bias in studies was assessed using the Joanna Briggs Inventory (JBI) for case reports (see
236	Supplementary Materials, Table S2) as case reports were the predominant type of manuscript expected for
237	the given review question. JBI for case reports assesses the risk of bias in included studies using eight
238	questions. These questions assess if: the patient's demographics are clearly defined; there is an adequate
239	description of the patient's history; the current condition is described comprehensively; results of
240	diagnostic tests and assessment methods are mentioned clearly; there is a clear description of treatment or
241	intervention procedures; there is a comprehensive assessment of post-intervention clinical condition; and
242	unanticipated or adverse events are adequately reported. Each question is answered in terms of yes, no,

243 unclear, and not applicable (Munn et al., 2020).

It is made available under a CC-BY-NC-ND 4.0 International license .

245 Data Extraction

After screening, manuscript data were extracted. Extracted data (see Table 2) included: author, year of publication, sample characteristics (including sample size, gender percentage of sample, mean age of the sample, or any other sample-specific characteristics), study design, study characteristics (outcome of the study), and results.

250

251 Table 2: Data Extraction table

Author,		Study	Sample		
Year	Country	Design	characteristics	Syndrome reported	Significant findings
Revuz et	France	Case	57-year-old	Immune	Severity of haemorrhagic syndrome
al., 2020		series	woman; 76-year-	Thrombocytopenic	not correlated with the severity of
			old man; 39-	Purpura (ITP)	COVID-19 infection. Intravenous
			year-old man		immunoglobulins(1g/kg) constituted
					best treatment for the syndrome.
Bennett et	USA	Case	73-year-old	Immune	The blood count of the patient was
al., 2020		report	woman	Thrombocytopenic	remarkable for leukopenia and seve
				Purpura (ITP)	thrombocytopenia. Platelets count o
					patients was <3k/µL. Patient was
					suspected of ITP and responded to t
					treatment of Intravenous
					immunoglobulins.

Author, Year	Country	Study Design	Sample characteristics	Syndrome reported	Significant findings
Otluoglu	Turkey	Case	48-year-old male	Viral encephalomyelitis	Acute lesions were found in the brai
et al.,		report			and upper cervical cord on MRI. Pa
2020					was treated with Hydroxychloroquin
					Favipiravir, Levetiracetam, and
					acyclovir.
Nicolotti	Italy	Case	44-year-old	Thrombotic	Patient was presented with acute kic
et al.,		report	woman	thrombocytopenic	injury, severe anemia, and respirato
2021				purpura (TTP)	failure due to COVID-19. Diagnosti
					tests confirmed TTP and patient wa
					treated with plasma exchange therap
					7 days and methylprednisolone there
					for 5 days.
Dhingra et	India	Case	35-year-old	Thrombotic	Blood examination of patient indica
al., 2021		report	woman	thrombocytopenic	thrombocytopenia (Platelets $20k/\mu L$
				purpura (TTP)	anemia (Hb-8.25) and signs of 8%
					schistocytes and hemolysis. Treatm
					included plasma exchange therapy v
					cryo poor plasma as a replacement f

Author,	G (Study	Sample		
Year	Country	Design	characteristics	Syndrome reported	Significant findings
Naous et	Lebanon	Case	69-year-old	Hemophagocytic	Patient was presented with hyperosi
al., 2021		report	woman	lymphohistiocytosis	state and high inflammatory marker
					Hemophagocytosis was shown in be
					marrow aspirate smear review. Patie
					died in spite of appropriate treatmer
Kalita et	India	Case	40-year-old	Hemophagocytic	Patient 1 was presented with bilater
al., 2021		series	woman; 2-year-	lymphohistiocytosis	crepitations and rhonchi. Treatment
			old man		patient included antibiotics, oxygen
					support, intravenous steroids, and
					heparin.
					Patient 2 was presented with feeding
					intolerance and abnormal body
					movement. Bone marrow smears we
					suggestive of hemophagocytic
					lymphohistiocytosis. The patient w ϵ
					treated with antibiotics, steroids, flu
					and anti-epileptic.

Author,	C	Study	Sample	C 1	<u>[]</u>
Year	Country	Design	characteristics	Syndrome reported	Significant findings
Tholin et	Norway	Case	70-year-old man	Hemophagocytic	Patient was admitted to the hospital
al., 2020		report		lymphohistiocytosis	complaints of diarrhea, fever, and
					abdominal pain. His health deteriora
					with time with marked rise in CRP,
					ferritin, and thrombocytopenia. His
					receptor level was elevated indicatii
					immune activation and bone marrov
					smear demonstrated hemophagocyte
					Patient was treated with tocilizumat
					800 mg intravenously, infusion of
					chimeric antigen receptor T cells.
Blitshteyn	USA	Case	Twenty patients	Autonomic disorders	Out of 20 patients, 15 had postural
&		series	(70% female)		orthostatic tachycardia (POTS), 2 h;
Whitelaw,					orthostatic hypotension, and 3 had
2021					neurocardiogenic syncope. Even aft
					8 months patients had residual autor
					symptoms.

Author,	a i	Study Sample		a 1		
Year	Country	Design	characteristics	Syndrome reported		Significant findings
Johansson	Sweden	Case	42-year-old	Postural	orthostatic	Patient 1 had palpitations, dizziness
et al.,		series	woman;	tachycardia s	yndrome	exercise intolerance. Non-
2021			28-year-old			pharmacological treatment included
			woman;			intake, avoidance of orthostatic trig
			37-year-old man			and compression stockings. Patient
						presented with symptoms of
						lightheadedness, chest pain, dyspne
						headache. POTS was confirmed by
						up tilt and active standing. Patient 3
						presented with fever, sore throat, m
						weakness, fatigue, and palpitations.
						Patient received pyridostigmine 10
						$\times 3$ and propranolol 10 mg $\times 3$ times
						day.

It is made available under a CC-BY-NC-ND 4.0 International license .

	Study	Sample		
	Design	characteristics	Syndrome reported	Significant findings
et Italy	Case	71-year-old male	Guillain-Barrè	Patient was presented with subacute
0	report		syndrome	onset of paresthesia with rapidly
				evolving flaccid tetraparesis. Biolog
				markers were interpreted as acute
				polyradiculoneuritis and diagnosis c
				Guillain-Barrè syndrome (GBS). Pa
				was treated with immunoglobulins (
				g/kg/d), hydroxychloroquine and
				antiviral therapy. Patient died 24 ho
				after the admission to the hospital.
al Iran	Case	65-years- old	Guillain-Barrè	Patient was presented with acute
ni,	report	male	syndrome	progressive symmetric ascending
				quadriparesis. Electrodiagnostic test
				confirmed the diagnosis of GBS. Pa
				was treated with IV immunoglobuli
				(0.4g/kg/d for 5 days).
)	CountryDesignetItalyCasec)report	Country Design characteristics et Italy Case 71-year-old male c) report	Country Design characteristics et Italy Case 71-year-old male Guillain-Barrè c) report syndrome

It is made available under a CC-BY-NC-ND 4.0 International license .

254 **Results**

255

256 *Characteristics of the study and sample*

257 Twelve studies (three case series, eight case reports, and one retrospective cohort study) based on the 258 inclusion criteria were included in the review. The studies that met the inclusion criteria were from 259 different regions around the globe. Six studies were from European regions: France (Revuz et al., 2020), 260 Turkey (Otluoglu et al., 2020), Norway (Tholin et al., 2020), Sweden (Johansson et al., 2021), and two 261 from Italy (Nicolotti et al., 2021; Alberti et al., 2020). Two studies were from North America (Bennett et 262 al., 2020; Blitshteyn & Whitelaw, 2021), four from Asia: two from India (Dhingra et al., 2021; Kalita et 263 al., 2021), and one each from Lebanon (Naous et al., 2021) and Iran (Sedaghal & Karimi, 2020). A total 264 of 36 patients constitute the sample size of the review. The age of the patients ranged from 28 years to 76 265 years, however, one study reported the case of a 2-year-old child experiencing post-COVID-19 syndrome 266 (Kalita et al., 2021).

267

268 Syndromes

269 All the included studies reported syndromes experienced by the patients after COVID-19 infection. The 270 syndromes reported in the literature include immune thrombocytopenic purpura (ITP), viral 271 encephalomyelitis, thrombotic thrombocytopenic purpura (TTP), hemophagocytic lymphohistiocytosis, 272 postural orthostatic tachycardia syndrome (POTS), and Guillain-Barrè syndrome (GBS). Two case reports 273 were on ITP (Revuz et al., 2020; Bennett et al., 2020). ITP diagnosis was determined based on reduced 274 platelet counts, an increased ferritin level, and thrombocytopenia, as indicated in bloodwork. In both case 275 reports of ITP, intravenous immunoglobulin (IVIG; 1 g/kg) constituted the first line of treatment and 276 patients responded well to the treatment. One of the included case studies was based on viral 277 encephalomyelitis experienced by patients after COVID-19 infection. Diagnosis was based on 278 hyperintense lesions, found on MRI, on the surface of the temporal lobe and posterior medial cortex. Two 279 cases of TTP were reported where the diagnosis was established based on: anemia, thrombocytopenia,

It is made available under a CC-BY-NC-ND 4.0 International license .

280 reduced activity of ADAMTS13 and increased activity of anti-ADAMTS13 antibodies. Plasma exchange 281 therapy was performed for both patients. One patient was given a fresh plasma transfusion followed by a 282 five-day course of methylprednisolone (Nicolotti et al., 2021) while the other patient received cyro-poor 283 plasma and received two doses of IM Vincristine and one dose of IM Rituximab (Dhingra et al., 2021). 284 Both patients recovered and were discharged. Three of the included case reports presented the case of 285 hemophagocytic lymphohistiocytosis (Tholin et al., 2020; Kalita et al., 2021; Naous et al., 2021). The 286 diagnosis was made based on bone marrow smears in all cases. The patients were treated with steroids, 287 antibiotics, and fluids. One patient was also infused with chimeric antigen receptor T-cells (Tholin et al., 288 2020). One of the patients did not survive despite high-dose steroid therapy and antibiotics (Naous et al., 289 2021). Other syndromes identified in the literature included POTS (Blitshteyn & Whitelaw, 2021; 290 Johansson et al., 2021) and GBS (Alberti et al., 2020; Sedaghal & Karimi, 2020). For POTS, the 291 diagnosis was confirmed using a head-up tilt test and measuring heart rate during active standing. 292 Acetylcholinesterase inhibitors and beta blockers were for the pharmacological treatment of POTS in 293 addition to non-pharmacological treatments such as abdominal binders, waist-high compression 294 stockings, and fluids. For GBS, the diagnosis was based on biological markers suggestive of 295 polyradiculoneuritis. IVIG constituted the first line of treatment. The details of each of the syndromes are 296 presented as follows.

297

298 Immune Thrombocytopenic Purpura

ITP is a bleeding disorder that is distinguished by a reduced number of platelets in the blood, known as isolated thrombocytopenia, where the platelet count is less than $150k/\mu/L$. It is a rare disease with a prevalence of 20 individuals per 1 million adults, typically affecting adults over the age of 50 (Michel, 2009). Pregnant women and those of childbearing age are also at increased (Provan & Newland, 2015). The disease course is generally more favourable in children than in adults. Children tend to achieve full remission sooner than adults, who often have a more chronic disease picture. Nonetheless, adults can

It is made available under a CC-BY-NC-ND 4.0 International license .

305 experience spontaneous remission, which typically occurs during the initial months of diagnosis.

306 Mortality is higher among older adults and patients who do not respond to initial treatment.

307 Pathophysiology

The pathophysiology of the disease is unclear. Many hypothesize that ITP results from the development of IgG autoantibody which targets structural glycoproteins IIb-IIIa situated on the platelet membrane (Stasi & Newland, 2011). This makes platelets prone to the process of phagocytosis by Kupffer cells and splenic macrophages in the liver. However, these autoantibodies have been identified in only 40-60% of patients with ITP (Nazy et al., 2018).

313

314 Clinical Symptoms

315 The initial suspicion and severity of ITP can be determined by evaluating the patient's skin and mucous 316 membranes, as well as asking them about their tendency to bruise or bleed minor trauma. As in other 317 primary haemostasis defects, mucocutaneous bleeding and deeper organ bleeding may occur. Clinical 318 signs of ITP include purpura, petechiae, and ecchymosis primarily in the upper and lower limbs. 319 Petechiae may also appear in mucosal membranes, such as the nasal septum, hard palate, or gums, leading 320 to epistaxis and gum bleeds. Spontaneous widespread hematomas can cause the platelet count to drop 321 below 10k μ/L . Although fatal complications are rare, ITP can be implicated in overt gastrointestinal 322 bleeding or intracerebral haemorrhage (Bohn & Steurer, 2018).

323

324 Treatment

Clinical observation typically begins when the platelet count drops to 30k/µL in the absence of active bleeding. Treatment is initiated when active bleeding occurs. Glucocorticoids are considered the first-line treatment and typically involve the administration of Prednisone at a dose of 1 mg/kg PO OD. If glucocorticoid therapy fails, Rituximab at a dose of 375 mg/m2 IV once/week for a month is considered the second line of treatment. In cases of refractory ITP, agents such as Romiplostim (1–10 mcg/kg once/week) and Eltrombopag (25–75 mg once/day) are often used (Bohn & Steurer, 2018). While full

It is made available under a CC-BY-NC-ND 4.0 International license .

remission can be achieved in approximately two-thirds of patients by splenectomy, this treatment comes with the risk of encapsulated bacterial infection and thrombosis. If patients do not respond to glucocorticoid treatment or experience severe bleeding, anti-D immunoglobulin (IG) or IVIG may be recommended.

- 335
- 336 Viral Encephalitis

337 Encephalitis is a condition characterized by inflammation of the brain parenchyma, which can result in 338 neurological dysfunction caused primarily by infection or autoimmunity. Diagnosis of encephalitis is 339 typically made through the identification of inflammation in brain tissue specimens, but since 340 inflammation in such specimens is not always directly indicated, indirect diagnoses must often be made 341 through ancillary non-invasive tests, including cerebrospinal fluid analysis and neuroimaging. It is 342 important to note that many other neurological conditions can lead to encephalopathy without causing any 343 evidence of inflammation in the parenchyma. Encephalitis is generally suspected when symptoms of 344 neurological dysfunction are observed, such as behavioral changes, focal deficits, decreased level of 345 consciousness, papilledema, seizures, and headaches, alongside systemic manifestations such as rash, 346 myalgia, arthralgia, lymphadenopathy, gastrointestinal symptoms, respiratory symptoms, or a history of 347 exposure to risk factors such as animal bites, endemic areas, or exposure to ticks or insects (Costa & Sato, 348 2020).

349

350 Pathophysiology

It has been suggested that a wide range of organisms can cause encephalitis, including protozoa, spirochetes, viruses, bacteria, fungi, and Rickettsiae. Among these, viruses are the most common cause of encephalitis worldwide; the most commonly implicated of which are cytomegalovirus (CMV), Herpes simplex virus (HSV1 and HSV2), varicella-zoster virus, chikungunya virus, Nipah virus, dengue virus, and enteroviruses (EVs). The pathophysiology of encephalitis can vary depending on the causative agent involved (Jain, Patel & Bhatt, 2014).

It is made available under a CC-BY-NC-ND 4.0 International license .

357

It is made available under a CC-BY-NC-ND 4.0 International license .

359 Clinical Signs

The major clinical signs of encephalitis include altered mental status, characterized by lethargy, decreased, or altered level of consciousness, or personality changes lasting for more than a day with no other alternative cause found; fever greater than 38°C within 72 hours before or after presentation; partial or generalized seizures that are not completely attributable to the patient's previous seizure disorder; recent onset of focal neurologic outcomes; neuroimaging suggestive of brain parenchyma abnormality; abnormalities detected in electroencephalography that are consistent with encephalitis and not attributable to any other cause.

367

368 Treatment

The first line of treatment for suspected encephalitis includes correction and supportive treatment for autonomic dysregulation, hepatic and renal dysfunction, and electrolyte disturbances. It is also important to treat non-convulsive status epilepticus and seizures. If the diagnosis is not confirmed within 6 hours of admission, then it is recommended to start treatment with acyclovir at 500 mg/m² TD for children and adolescents and 10 mg/kg TD for adults. Doses should be adjusted if the patient has a previous history of renal impairment (Costa & Sato, 2020).

375

376 Thrombotic Thrombocytopenic Purpura (TTP)

377 TTP is classified as a type of thrombotic microangiopathy (TMA), a diverse set of disorders characterized 378 by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction resulting from 379 disturbed microcirculation. TTP is a rare disorder occurring in approximately 5 individuals per 1 million 380 annually.

381

382 Pathophysiology

In current literature, the pathophysiology of TTP is described as a severe deficiency of ADAMTS13,
which can be the result of autoantibodies affecting its function, genetic abnormalities (congenital TTP), or

385 dysregulated clearance of ADAMTS13 (autoimmune TTP). Persistent UL-VWF MM (ultra-large VWF 386 multimers) results in the deficiency of ADAMTS13. UL-VWF MM with enhanced platelet aggregation 387 occurs in the presence of stress-causing agents including, but not limited to, infections, pregnancy, 388 surgery, and certain drugs. The aggregation of platelets causes an impedance in the flow of blood in the 389 microcirculation, leading to clinical symptoms and organ damage. Although the central nervous system 390 (CNS) is mainly affected by TTP, it also has an impact on other organs, including the heart and kidneys. 391 In patients with acute TTP, platelets rich in von Willebrand factor with no or low fibrin have been 392 identified in capillaries, small vessels, and large vessels (Lämmle, Hovinga & Alberio, 2005).

393

394 Clinical Signs

395 Clinical signs of thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies 396 (TMAs) are characterized by disturbances in the microcirculation, consumption thrombocytopenia, and 397 symptoms of red cell fragmentation (such as Coombs-negative hemolysis). Red cell fragmentation can be 398 detected by free serum hemoglobin, elevated LDH, anemia, schistocyte count, reticulocyte count, 399 hemoglobinuria, and reduced haptoglobin levels (Knöbl, 2013). Neurological symptoms resulting from 400 brain hypoperfusion, such as blurry speech, headache, dizziness, amaurosis, epileptic seizures, stroke, or 401 coma, can also occur due to TTP. Kidney involvement can lead to increased oligo- or anuria, serum 402 creatinine, and hemolysis-induced hemoglobinuria. Thrombocytopenia may not always present with 403 purpura and bleeding is rare, but hemolysis can cause anemia and jaundice. Cardiac involvement is a 404 dangerous complication for patients with TTP (Mariotte et al., 2016).

405

406 *Treatment*

407 Plasma exchange therapy is considered the first-line treatment for TTP and has been shown to improve 408 the survival rate of 80-90% of patients. The therapy involves replacing 1.5 times the patient's plasma 409 volume with donor plasma. The donor plasma used can either be virus-inactivated plasma, fresh frozen 410 single donor plasma, pooled donor plasma, or cryosupernatant. During therapy, the UL-VWF MM,

It is made available under a CC-BY-NC-ND 4.0 International license .

autoantibodies, sludges, and immune complexes that are responsible for TTP are removed. This helps inreducing the severity of symptoms and improving the patient's condition.

413 Plasma infusion

414 It's important to note that plasma infusion is not typically considered the first-line treatment for TTP. 415 However, in patients with congenital TTP (a rare genetic form of the disorder), plasma infusion may be 416 used as a treatment to replace the missing enzyme ADAMTS13. In these cases, regular prophylactic 417 plasma infusions may also be necessary to prevent further episodes of the disease. The recommended 418 dose for plasma infusion in TTP can vary depending on the severity of the disease and the patient's 419 individual needs.

420

421 Immunosuppression

422 If TTP is autoimmune, then immunosuppression is achieved through corticosteroids such as prednisone 1423 2 mg/kg to suppress the formation of other antibodies. In other forms of thrombotic microangiopathies,
424 steroids are administered to reduce stress and enhance endothelial function (Zheng et al., 2020).

425

426 *Hemophagocytic Lymphohistiocytosis (HLH)*

427 HLH is an uncommon but serious immunological syndrome characterized by elevated macrophage 428 activity and cytotoxic lymphocytes, leading to multi-organ dysfunction and cytokine-mediated tissue 429 injury. Several key soluble mediators including IL-18, interleukin (IL)-1b, and Interferon-gamma (IFN- γ) 430 characterize HLH immunopathology. HLH has been classified into two forms: primary/familial form (F-431 HLH) and reactive/sporadic/secondary form. Familial HLH is conferred by the presence of penetrant 432 genetic variation and mutation which affects lymphocyte survival, cytolytic function, and inflammasome 433 activation. On the other hand, acquired factors such as infection, malignancy, and chronic inflammation 434 constitute the basis for reactive HLH (Grom, Horne & De Benedetti, 2016).

435

436 Pathophysiology

It is made available under a CC-BY-NC-ND 4.0 International license .

437 The underlying mechanism of HLH is yet to be elucidated. HLH is a distinct state of the activated 438 immune system which can be achieved through several pathways depending on the environmental 439 triggers and predispositions of the individual. Note that HLH is primarily driven by the abnormal immune 440 system of an individual as opposed to underlying triggering agents. Moreover, the immune response in 441 HLH, mediated by the activation of cytotoxic T-cells (CD8b T-cells in particular) differs from the 442 immune response in autoimmune disease as it does not target self-antigen agents. Chronic inflammation 443 and immunosuppression also serve as predisposing factors for HLH. In such conditions, HLH is mostly 444 triggered by viruses, but intracellular pathogens can also serve as triggering agents (Allen & McClain, 445 2015). Genetic mutations leading to HLH are clustered around the genes responsible for proteins 446 implicated in lymphocyte activation and survival as well as cell-mediated cytotoxicity.

447

448 Clinical Signs

Early diagnosis of HLH is crucial as patients can rapidly progress to multiorgan failure and death. Patients with HLH typically present with a persistently high fever, as well as other symptoms such as lymphadenopathy, hepatomegaly, splenomegaly, dysfunction of the CNS (including seizures or altered mental status), coagulopathy, and liver dysfunction. In some cases, patients may develop shock (Ramos-Casals et al., 2014). A common feature of HLH is a persistent high fever that does not respond to standard fever-reducing medications. Hepatomegaly is present in both children and adults with HLH, while splenomegaly is common but not present in all cases.

456

457 Treatment

The treatment approach for HLH depends on the severity of the disease and the underlying triggering agent, if identified. The primary goal of treatment is to control inflammation, which is the underlying mechanism driving the disease. A multidisciplinary team approach is often necessary to provide comprehensive care for patients with HLH. Supportive care with blood products may be necessary for

It is made available under a CC-BY-NC-ND 4.0 International license .

- 462 patients with abnormal blood clotting, and ventilator support may be required for critically ill patients
- 463 with respiratory failure (Janka & Lehmberg, 2013).

464

It is made available under a CC-BY-NC-ND 4.0 International license .

466 *Postural Orthostatic Tachycardia Syndrome (POTS)*

467 POTS is a clinical syndrome that presents with a variety of symptoms experienced by patients while 468 standing, including palpitations, light-headedness, generalized weakness, tremors, exercise intolerance, 469 blurred vision, and fatigue. A hallmark of POTS is an increase in heart rate of at least 30 bpm (or at least 470 40 bpm in individuals aged 12-19 years) within 10 minutes of moving from a reclining to a standing 471 position. POTS is diagnosed when orthostatic hypotension, defined as a drop in systolic blood pressure of 472 at least 20 mmHg, is absent. Presyncope symptoms are common in patients with POTS; standing heart 473 rate is typically \geq 120 bpm and higher in the morning than in the evening.

474

475 Pathophysiology

476 Assuming an upright posture typically results in blood shifting from the chest to the legs and lower 477 abdomen, and a significant volume of plasma moving from the vasculature to the interstitial space. This 478 plasma shift can reduce venous return and lead to decreased stroke volume, cardiac filling, and arterial 479 pressure. The compensatory sympathetic response, activated by baroreceptor signalling, can increase 480 heart rate and systemic vasoconstriction, which restores cardiac output and venous return. In POTS, 481 however, these physiological regulations are often compromised, resulting in reduced cardiac output, lack 482 of normalization of cardiac volume, reduced venous return, and enhanced heart rate while standing. The 483 underlying pathophysiology of POTS is not fully understood, but multiple factors likely contribute to the 484 disorder, resulting in varied symptoms among individuals. Symptoms of POTS may result from excessive 485 orthostatic shift in plasma volume, hypovolemia, increased sympathetic tone, enhanced blood venous 486 pooling or poor venous return, physical deconditioning, autonomic dysfunction, and immunological 487 factors (Wells et al., 2017).

488

489 Clinical Signs

Orthostatic symptoms are the most frequent clinical manifestations of POTS, and they can be divided into
 non-cardiac symptoms (such as light-headedness, headaches/migraines, brain fog, nausea, weakness,

It is made available under a CC-BY-NC-ND 4.0 International license .

492 tunnel/blurred vision, fatigue, and tremulousness) and cardiac symptoms (such as chest discomfort, 493 exercise intolerance, dyspnoea, and heart palpitations). Light-headedness and presyncope are the most 494 commonly reported symptoms in POTS, although only 30% of patients faint. It is important to note, 495 however, that symptoms of POTS can also be non-orthostatic and general, including problems with 496 sleeping, fatigue, migraines, daytime sleepiness, and hypermobility of joints (Mar & Raj, 2020).

497

498 *Treatment*

The treatment of POTS involves both pharmacological and non-pharmacological approaches. Nonpharmacological treatments, which should be the first line of treatment, include exercise, increased salt and fluid intake, muscle tensing, using compression garments, modifying diet, and discontinuing medications that worsen the symptoms. POTS patients should also avoid stressors such as alcohol consumption, extreme heat, and dehydration.

504

505 Pharmacological treatments for POTS target the underlying cause of the disorder and aim to reduce heart 506 rate, improve peripheral vasoconstriction, and increase intravascular volume. Midodrine and 507 fludrocortisone are the most commonly prescribed medications, but their side effects may not be well-508 tolerated by some patients.

509

510 Guillain-Barrè syndrome (GBS)

GBS is a rare, but serious, neurological disorder characterized by flaccid, acute, and neuromuscular paralysis. It was first described over a century ago, and since then, numerous studies have been conducted to investigate its presentation, immune-mediated pathophysiology, prognostic models, and treatment outcomes (Yuki & Hartung, 2012). GBS is typically classified as an "acute inflammatory demyelinating polyradiculopathy" because it affects the spinal cord and peripheral nerves, causing inflammation and damage to the myelin sheath that surrounds and protects nerve fibers. This damage can result in muscle weakness, arflexia, and sensory deficits, among other symptoms.

It is made available under a CC-BY-NC-ND 4.0 International license .

518 Pathophysiology

GBS is considered to be an autoimmune disorder in which the immune system mistakenly attacks the myelin sheath covering nerve fibers in the peripheral nervous system (PNS). This results in inflammation, demyelination, and, in severe cases, axonal degeneration. The attack on the myelin sheath and nerve fibers leads to a breakdown in communication between the nerves and muscles, resulting in the characteristic flaccid paralysis seen in GBS (Leonhard, Ziemann, & Spies, 2021). The exact cause of GBS is not fully understood, but it is believed to be triggered by a preceding infection or vaccination in some cases.

526

527 Clinical Signs

528 GBS is characterized by distal and proximal weakness, which can be flaccid and profound when the 529 patient is hospitalized. As the disease progresses, patients may require intubation due to respiratory 530 muscle weakness. GBS may also present with hyporeflexia and areflexia. Sensory symptoms, which are 531 length-dependent, accompany the areflexia and flaccid weakness. Facial diplegia can also develop as both 532 of the facial cranial nerves may be involved (Fokke et al., 2014).

533

534 Treatment

The first-line treatments for GBS are plasma exchange therapy and IVIG. Plasma exchange therapy removes humoral mediators, pathogenic antibodies, and complement proteins, which are often pathogenic agents for GBS (Chevret, Hughes & Annane, 2017). IVIG exerts its therapeutic effects through immunemodulating actions.

539

540 Discussion

541 The objective of the systematic review was to identify and characterize post-COVID-19 infection 542 syndromes. The review identified six syndromes described in the literature, and a qualitative synthesis

It is made available under a CC-BY-NC-ND 4.0 International license .

543 was conducted to synthesize the literature around their diagnosis and treatment methods. Here, we 544 hypothesise potential mechanisms of how COVID-19 infection may lead to each of these syndromes.

545 Several pathways have been proposed that may lead to thrombocytopenia after COVID-19 infection, 546 including the interaction of platelets with the virus through pathogen recognition receptors, 547 hemophagocytosis caused by cytokine storms, sepsis, immune complexes and autoantibodies against 548 platelets, platelet activation in lung tissue leading to coagulopathy, and microthrombi formation and 549 damaged lung tissue leading to reduced platelet counts from megakaryocytes (Xu, Zhou & Xu, 2020). 550 However, the most common mechanism leading to ITP is thought to be molecular mimicry between 551 platelet glycoproteins and viral components. A study by Zhang et al. (2009) showed that protein 552 sequences are shared between glycoprotein IIIa found on platelets and hepatitis C core-envelope peptides, 553 which can trigger the production of antibodies that can fragment platelets. However, no sequence 554 homology has been identified between platelet components and SARS-CoV-2 infection, so the exact 555 mechanism remains unclear.

556

557 Three major pathways describe the underlying mechanism of SARS-CoV-2 infection causing 558 encephalitis: the blood circulation pathway, direct infection injury, and neuronal pathways. Given that we 559 know the functional receptor for the SARS-CoV-2 virus to be the ACE-2 receptor, which is present on the 560 capillary endothelium, glial cells, and neurons, the blood circulation pathway suggests that these cells are 561 thus potential targets for the virus, which may then enter the CNS through said receptors (Zhao et al., 562 2020). Another mechanism is the direct entry of the virus through the cribriform plate in the brain. Since 563 the SARS-CoV-2 virus usually replicates in the nasopharyngeal epithelium, it can cause damage to 564 neuronal tissue in the same manner as it does in olfactory nerves (Corona, Rodríguez-Violante & 565 Delgado-García, 2020). Dynein and kinesin proteins in nerves, such as the vagus nerve, may also be 566 responsible for the retrograde and anterograde transportation of the virus in the brain, facilitating insult 567 via neuronal pathways (Zhao et al., 2020).

It is made available under a CC-BY-NC-ND 4.0 International license .

Viruses are known to commonly trigger thrombotic microangiopathies, but the exact mechanism leading to TTP from COVID-19 infection is unknown. However, several pathways have been proposed, including a high inflammatory state associated with cytokine storms, direct endothelial injury, or mediation via enhanced procoagulant factors such as von Willebrand factor, fibrinogen, and factor VIII (Panigada et al., 2020). Pascreau et al. (2021) observed 70 COVID-19 patients and determined their antigen levels, plasma VWF activity, and ADAMTS 13 antigen levels. They found a marked increase in VWF levels, which was associated with a decrease in ADAMTS13 levels, a pathognomonic indicator for TTP.

576

It has been proposed in the literature that the SARS-CoV-2 virus can cause cytokine storm including HLH, as there are many similarities in the clinical presentation of COVID-19 and HLH (Mehta et al., 2020). Poor outcomes have been observed for patients with SARS-CoV and MERS, which are associated with enhanced levels of proinflammatory cytokines (e.g., IL-1 β) in body tissues, specifically in the lower respiratory tract (He et al., 2006). Increased levels of IL-1 β enhance the production of other proinflammatory cytokines, including IL-6 and TNF- α , which can result in cytokine storm (Nieto-Torres et al., 2014). Therefore, SARS-CoV-2 may trigger secondary HLH in some patients.

584

The proposed mechanism for POTS post-COVID-19 infection is the dysregulation of the reninangiotensin-aldosterone system (RAAS) due to the interaction of the SARS-CoV-2 virus with ACE2 receptors. ACE2 receptors are found on the endothelial cells of various organs including the lungs, heart, and kidneys; and we know that the virus binds to these receptors to enter the cell. This interaction can result in the downregulation of ACE2 receptors, which leads to an increase in angiotensin II levels, resulting in vasoconstriction, inflammation, and oxidative stress. This can lead to endothelial dysfunction and microvascular damage, ultimately leading to the development of POTS (Kanjwal et al., 2021).

592

593 It has been proposed in the literature that SARS-CoV-2 causes GBS syndrome in some patients either 594 directly by binding with ACE2 receptors on neuronal tissue and manifesting their neuroinvasive capacity

It is made available under a CC-BY-NC-ND 4.0 International license .

595 or indirectly through an autoinflammatory mechanism. Molecular mimicry may also play a role in the 596 development of GBS in some COVID-19 patients. Molecular mimicry occurs when the immune system 597 mistakes a viral protein for a self-protein, leading to an autoimmune response against the body's tissues. A 598 study by Toscano et al. (2020) reported that five COVID-19 patients with GBS had antibodies against 599 gangliosides, which are molecules found on nerve cell membranes that can be targeted by the immune 600 system in GBS. The antibodies were found to cross-react with the SARS-CoV-2 spike protein, supporting 601 a potential role of molecular mimicry as the underlying mechanism. However, more research is needed to 602 fully understand the mechanisms underlying GBS in COVID-19.

603

604 Conclusions

605 Since the emergence of Coronavirus infectious Disease 2019 (COVID-19) in late December 2019, several 606 vaccines have been made which subsided the pandemic; however post-COVID-19 infection, multiple 607 syndromes have been reported globally. The intention of writing this systemic review is to summerise all 608 the reported cases and hypothesised pathophysiology that might have led to the manifestation of the 609 syndrome. Total of 12 studies were included which met the eligibility criteria where the reported studies 610 immune thrombocytopenic purpura (ITP), viral encephalomyelitis, were: hemophagocytic 611 lymphohistiocytosis, thrombotic thrombocytopenic purpura (TTP), Guillain-Barrè syndrome (GBS) and 612 postural orthostatic tachycardia syndrome (POTS). Furthermore, presenting symptoms and treatment for 613 each respective syndrome were discussed with brief background on coronavirus and its variants to 614 provide a foundation on which to examine the syndromes manifested after COVID-19 infection.

- 615
- 616
- 617
- 618
- 619
- 620

It is made available under a CC-BY-NC-ND 4.0 International license .

621

It is made available under a CC-BY-NC-ND 4.0 International license .

623 **Declarations**

624

- 625 *Competing interests*
- 626 The authors declare that they have no competing interests.

627

- 628 Funding
- 629 None.

630

631 Authors' contributions

632 SA conceptualised the systematic review and prepared the initial draft of the manuscript. AZ 633 supported writing of the draft and oversaw its critical review and editing. *Both SA and AZ 634 contributed equally to this work as co-first-authors. SK, AT, and KT undertook the literature 635 search and helped prepare the manuscript draft. All authors read and approved the final 636 manuscript.

637

- 638
- 639
- 640
- 641

642

It is made available under a CC-BY-NC-ND 4.0 International license .

648 **References**

- 649 Allen, C. E., & McClain, K. L. (2015). Pathophysiology and epidemiology of hemophagocytic
- 650 lymphohistiocytosis. Hematology 2014, the American Society of Hematology Education Program

651 *Book*, 2015(1), 177-182.

652

Aromataris, E. and Pearson, A., 2014. The systematic review: an overview. *AJN The American Journal of Nursing*, *114*(3), pp. 53-58.

655

- 656 Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021). SARS-CoV-2 variants evolved during the
- 657 early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. *International*

658 *journal of biological sciences*, 17(1), 97.

659

Bohn, J. P., & Steurer, M. (2018). Current and evolving treatment strategies in adult immune
thrombocytopenia. *memo-Magazine of European Medical Oncology*, 11(3), 241-246.

662

663 Carod-Artal, F. J. (2020). Neurological complications of coronavirus and COVID-19. *Revista de* 664 *neurologia*, 70(9), 311-322.

665

Casalino, L., Gaieb, Z., Goldsmith, J. A., Hjorth, C. K., Dommer, A. C., Harbison, A. M. & Amaro, R. E.
(2020). Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. *ACS central science*, 6(10), 1722-1734.

669

- 670 Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019 (COVID671 19).[Accessedon30/11/2022]Availablefrom:
- 672 https://www.cdc.gov/coronavirus/2019ncov/variants/index.html?CDC_AA_refVal=https%3A%2F%2Fw
- 673 ww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fabout-variants.html

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296022; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 674 Challen, R., Brooks-Pollock, E., Read, J. M., Dyson, L., Tsaneva-Atanasova, K., & Danon, L. (2021).
- 675 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort
- 676 study. BMJ, 372. doi: 10.1136/bmj.n579
- 677
- 678 Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: genome structure, replication, and 679 pathogenesis. *Journal of medical virology*, 92(4), 418-423.
- 680
- 681 Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., ... & Team, N. I. C. (2021). SARS-
- 682 CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in
- 683 Maharashtra, India. *Microorganisms*, 9(7), 1542.
- 684
- 685 Chevret, S., Hughes, R. A., & Annane, D. (2017). Plasma exchange for Guillain □Barré syndrome.
 686 Cochrane Database of Systematic Reviews, doi: 10.1002/14651858.CD001798.pub3.
- 687
- 688 Corona, T., Rodríguez-Violante, M., & Delgado-García, G. (2020). Neurological manifestations in
 689 coronavirus disease 2019. Gaceta médica de México, 156(4), 313-316.
- 690
- 691 Costa, B. K. D., & Sato, D. K. (2020). Viral encephalitis: a practical review on diagnostic approach and
 692 treatment. Jornal de Pediatria, 96, 12-19.
- 693
- 694 Coronavirus cases: Worldometer. (n.d.). https://www.worldometers.info/coronavirus/

695

Dong, N., Yang, X., Ye, L., Chen, K., Chan, E. W. C., Yang, M., & Chen, S. (2020). Genomic and
protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296022; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 698whichcausedapneumoniaoutbreakinWuhan,China.BioRxiv.699https://doi.org/10.1101/2020.01.20.913368
- 700
- 701 Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and 702 pathogenesis. Coronaviruses, 1-23.
- 703
- Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., & Jacobs, B. C. (2014).
- 705 Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain, 137(1), 33-43.
- 706
- 707 Garland, E. M., Celedonio, J. E., & Raj, S. R. (2015). Postural tachycardia syndrome: beyond orthostatic

intolerance. Current neurology and neuroscience reports, 15(9), 1-11.

- 709
- Grom, A. A., Horne, A., & De Benedetti, F. (2016). Macrophage activation syndrome in the era of
 biologic therapy. Nature Reviews Rheumatology, 12(5), 259-268.
- 712
- 713 Guilmot, A., Maldonado Slootjes, S., Sellimi, A., Bronchain, M., Hanseeuw, B., Belkhir, L.& Van Pesch,
- V. (2021). Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. Journal of
 neurology, 268(3), 751-757.
- 716
- He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., ... & Jiang, S. (2006). Expression of elevated
 levels of pro inflammatory cytokines in SARS CoV infected ACE2+ cells in SARS patients: relation
 to the acute lung injury and pathogenesis of SARS. The Journal of Pathology: A Journal of the
 Pathological Society of Great Britain and Ireland, 210(3), 288-297.
- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019).
- 722 Cochrane Handbook for Systematic Reviews of Interventions (2nd ed.). John Wiley & Sons. ISBN: 978-
- 723 1-119-26361-2 (paperback); 978-1-119-26362-9 (e-book).

It is made available under a CC-BY-NC-ND 4.0 International license .

724

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2019).
Cochrane Handbook for Systematic Reviews of Interventions (2nd ed.). John Wiley & Sons.
Imbach, P., & Crowther, M. (2011). Thrombopoietin-receptor agonists for primary immune
thrombocytopenia. New England Journal of Medicine, 365(8), 734-741.
Jain, S., Patel, B., & Bhatt, G. C. (2014). Enteroviral encephalitis in children: clinical features,
pathophysiology, and treatment advances. Pathogens and global health, 108(5), 216-222.
Janka, G. E., & Lehmberg, K. (2013). Hemophagocytic lymphohistiocytosis: pathogenesis and treatment.
Hematology 2013, the American Society of Hematology Education Program Book, 2013(1), 605-611.
Kamble, P., Daulatabad, V., Patil, R., John, N. A., & John, J. (2022). Omicron variant in COVID-19
current pandemic: a reason for apprehension. Hormone Molecular Biology and Clinical Investigation,
44(1), 89-96. doi: 10.1515/hmbci-2022-0010.
Knöbl, P. (2013). Treatment of thrombotic microangiopathy with a focus on new treatment
options. Hämostaseologie, 33(02), 149-159.
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., & Montefiori, D. C.
(2020). Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the
COVID-19 virus. Cell, 182(4), 812-827.
Kupferschmidt, K., & Wadman, M. (2021). Delta variant triggers new phase in the pandemic. Science
372, 1375-1376 doi:10.1126/science.372.6549.1375

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296022; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Lämmle, B., Hovinga, J. K., & Alberio, L. (2005). Thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, *3*(8), 1663-1675.

- Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of
- 754 COVID-19. Journal of pharmaceutical analysis, 10(2), 102-108.
- 755
- Li, Z., Tomlinson, A. C., Wong, A. H., Zhou, D., Desforges, M., Talbot, P. J., Benlekbir S., Rubinstein
 J.L, Rini, J. M. (2019). The human coronavirus HCoV-229E S-protein structure and receptor
 binding. *Elife*, 2019 Oct 25; 8:e51230. doi: 10.7554/eLife.51230
- 759
- Mallapaty, S. (2021). Delta's rise is fuelled by rampant spread from people who feel fine. Nature,
 596(August), 19. doi: 10.1038/d41586-021-02187-1
- 762
- Mar, P. L., & Raj, S. R. (2020). Postural orthostatic tachycardia syndrome: mechanisms and new
 therapies. Annual Review of Medicine, 71(1), 235-248. doi: 10.1146/annurev-med-042718-043351.
- 765
- Mariotte, E., Azoulay, E., Galicier, L., Rondeau, E., Zouiti, F., Boisseau, P., ... & French Reference
 Center for Thrombotic Microangiopathies. (2016). Epidemiology and pathophysiology of adulthood-onset
 thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic
 purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. *The Lancet Haematology*, *3*(5), e237-e245.doi: 10.1016/S2352-3026(16)00032-4.
- 771
- Mark Vrabel, M.L.S., 2015, September. Preferred reporting items for systematic reviews and metaanalyses. In *Oncology nursing forum* (Vol. 42, No. 5, p. 552). Oncology Nursing Society

medRxiv preprint doi: https://doi.org/10.1101/2023.09.24.23296022; this version posted September 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

774	Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19:
775	consider cytokine storm syndromes and immunosuppression. Lancet, 395(10229), 1033-1034. doi:
776	10.1016/S0140-6736(20)30628-0.

- 777
- Michel, M. (2009). Immune thrombocytopenic purpura: epidemiology and implications for
 patients. *European Journal of Haematology Suppl.*, 71: 3-7.
- 780
- 781 Mishra, S., Mindermann, S., Sharma, M., Whittaker, C., Mellan, T. A., Wilton, T.& COVID, T. (2021).
- 782 Changing composition of SARS-CoV-2 lineages and rise of Delta variant in
 783 England. *EClinicalMedicine*, 39:101064.
- 784
- Morley, V. J., & Turner, P. E. (2017). Dynamics of molecular evolution in RNA virus populations depend
 on sudden versus gradual environmental change. *Evolution*, *71*(4), 872-883.
- 787
- Moschcowitz, E. L. I. (1924). Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto
 undescribed disease. In *Proc NY Pathol Soc* (Vol. 24, No. 1, pp. 21-24).
- 790
- Munn, Z., Barker, T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., ... & Aromataris, E. (2020).
 Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. *JBI evidence synthesis*, 18(10), 2127-2133.
- 794
- Nakagawa, K., Lokugamage, K. G., & Makino, S. (2016). Viral and cellular mRNA translation in
 coronavirus-infected cells. *Advances in virus research*, *96*, 165-192.
- Nazy, I., Kelton, J. G., Moore, J. C., Clare, R., Horsewood, P., Smith, J. W.& Arnold, D. M. (2018).
 Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune
 thrombocytopenia.

- 0.0.2

- - _